| Title |
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, April 2011
|
| DOI | 10.1186/alzrt75 |
| Pubmed ID | |
| Authors |
François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine |
| Abstract |
Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. As the brain is rich in mast cells, the therapeutic potential of masitinib as an adjunct therapy to standard care was investigated. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Russia | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 190 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 16% |
| Student > Master | 29 | 15% |
| Student > Ph. D. Student | 24 | 12% |
| Student > Bachelor | 24 | 12% |
| Other | 13 | 7% |
| Other | 30 | 16% |
| Unknown | 43 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 19% |
| Agricultural and Biological Sciences | 21 | 11% |
| Neuroscience | 19 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 8% |
| Biochemistry, Genetics and Molecular Biology | 12 | 6% |
| Other | 32 | 17% |
| Unknown | 56 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 173. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2022.
All research outputs
#232,932
of 25,374,917 outputs
Outputs from Alzheimer's Research & Therapy
#33
of 1,465 outputs
Outputs of similar age
#718
of 120,155 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 4 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,465 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,155 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them